{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-007286","form_type":"8-K","ticker":"JANX","cik":"0001817713","company_name":"Janux Therapeutics, Inc.","filed_at":"2023-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.738519+00:00","generated_at":"2026-06-18T05:44:31.127227+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Janux Therapeutics posts 2022 net loss of $63.1M; cash at $327M; JANX007 update expected 2H 2023","bullets":["Net loss of $63.1M for FY2022, vs $32.7M in FY2021; R&D expenses doubled to $53.4M.","Cash and short-term investments $327.0M at Dec 31, 2022, down from $375.0M at Dec 31, 2021.","FDA clearance for JANX008 (EGFR-TRACTr) IND; JANX009 IND submission on track 2023.","Interim clinical update from JANX007 (PSMA-TRACTr) Phase 1 trial expected in H2 2023.","Janux states SVB exposure is immaterial and will not impact short- or long-term objectives."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-007286","json":"https://secwatch.observer/filing/0000950170-23-007286.json","markdown":"https://secwatch.observer/filing/0000950170-23-007286.md","text":"https://secwatch.observer/filing/0000950170-23-007286.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817713/000095017023007286/0000950170-23-007286-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817713/000095017023007286/janx-20230310.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T05:44:31.127227+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"34f65af0adb71e8695b7a75d11949c36dd57cbd5","claim":"Janux Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2022 results: net income Net loss was $16.1 million for the quarter and $63.1 million for the year ended December 31, 2022.","evidence_excerpt":"Janux Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1817713/000095017023007286/0000950170-23-007286-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2022"},{"label":"Net income","value":"Net loss was $16.1 million for the quarter and $63.1 million for the year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}